TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06194318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate vaccine, SCB-1019
Description: The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT06306677

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-clincial-based hybrid system for radiographic image analysis
Description: The Index test is a novel AI-clinical-based hybrid system for radiographic image analysis. Its diagnostic performance will be compared to the reference represented by a panel of experts.
Study: NCT05804981

Intervention type: OTHER
Group type: OTHER
Intervention: PRO-CS
Description: 4 questions about cognitive function added to annual wellness visit protocol
Study: NCT06001827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfWrap Bioabsorbable Perivascular Wrap
Description: SelfWrap is applied during arteriovenous fistula (AVF) creation surgery. It provides mechanical support to improve maturation and patency of AVFs.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Untreated AVF Control
Description: AVF creation surgery without any intervention
Study: NCT04876651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-rosopatamb
Description: Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-rosopatamb
Description: Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best SoC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: enzalutamide or abiraterone \[+ prednisone/prednisolone)\] or docetaxel
Study: NCT05805683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: patients in this group will receive 100 IU (1 ml) of calcitonin subcutaneously per day for 2 weeks starting within 48 hours after injury.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients in this group will receive 1 ml of saline placebo solution subcutaneously per day for 2 weeks starting within 48 hours after injury.
Study: NCT06226142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous dilatational tracheostomy
Description: Percutaneous dilatational tracheostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous dilatational tracheostomy
Description: Percutaneous dilatational tracheostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous dilatational tracheostomy
Description: Percutaneous dilatational tracheostomy
Study: NCT05460221

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optimized oil group
Description: This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional oil group
Description: This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months.
Study: NCT04787900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPhone measurement application
Description: The iPhone measurement application will be used to ensure validity and reliability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bubble inclinometer
Description: Bubble inclinometer with proven validity and reliability will be used for this study.
Study: NCT05876364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP104 1ug
Description: Intramuscular injections of 1 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP104 5ug
Description: Intramuscular injections of 5 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QTP104 25ug
Description: Intramuscular injections of 25 µg of novel Lipid-Inorganic Nanoparticle (LION) formulated replicating RNA-based vaccine (QTP104) on days 1 and 28
Study: NCT05460221

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: This is a controlled parallel study. The patient will receive 25 mL/day of three different types of olive oils with different amouns of bioactive compounds from the olive tree, that must be consumed throughout the day at breakfast or snack (depending on the habits of each child). The doses that they do not take must be returned to the hospital staff to assess adherence to the intervention. The families will receive the same type of oil so that they can cook with it during the study period.~The control oil will be the same extra virgin olive oil washed to decrease bioactive components (approx. 125 ppm).~The intervention will take place for 6 months.
Study: NCT05250531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multicomponent therapy
Description: patient education,Exercise training,Private Psychotherapy,relaxation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multicomponent therapy
Description: patient education,Exercise training,Private Psychotherapy,relaxation
Study: NCT05081843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AD IT UP media literacy intervention
Description: AD IT UP was originally developed in 2006 as a classroom-based cigarette prevention program focused on traditional media influences, and was converted to a web-based program in 2011. In 2019, the AD IT UP program was updated substantially to include other forms of tobacco, such as e-cigarettes, and other forms of media, such as social media.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual health education curriculum
Description: The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual health education curriculum
Description: The schools' regular health education curriculum includes classroom lectures, hands on activities and group work.
Study: NCT04827082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Description: Diacutaneous fibrolysis is a physiotherapeutic instrumental technique, used to treat musculoskeletal conditions causing pain and/or movement restriction. It is applied by means of metallic hooks, ending in a spatula with beveled edges. Regardless of its own dominance, diacutaneous fibrolysis will be applied to de following muscles and intermuscular septums: gluteus maximus, biceps femoris and semitendinosus to de lower experimental limb. A single session of 10 minutes will be applied.
Study: NCT05210465

Intervention type: OTHER
Intervention: speckle tracking mode of the stress ECHO test with dobutamine
Description: speckle tracking mode of the stress ECHO test with dobutamine
Study: NCT04981834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo RARP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: Undergo RARP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vesicopexy
Description: Undergo vesicopexy
Study: NCT06482723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mGlobal L+AS
Description: The investigated dermal filler mGlobal L+AS is intended to be used as a temporary filler, administered by intradermal or subcutaneous injections, to correct small skin defects, such as wrinkles or scars.
Study: NCT04079257

Intervention type: OTHER
Intervention: Blood collection for measurement of eculizumab peak concentrations
Description: collection of blood
Study: NCT06332573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Onco-sexology support
Description: Initiation of onco-sexology support before the introduction of systemic oncology treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Onco-sexology support
Description: Initiation of onco-sexology support after the introduction of systemic oncology treatment (2-3 months after the start of treatment).
Study: NCT06492265

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Emergency Stroke Unit based on 0.23-T MRI
Description: The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by Emergency Stroke Unit process based on low-field magnetic resonance imaging.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard stroke unit adherent to guidelines
Description: The participants with hyperacute ischemic stroke (between 4.5-6 hours after onset of symptoms) who are eligible to receive reperfusion therapy will be managed by standard stroke unit process adherent to guidelines.
Study: NCT05885295

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI brain, Blood tests, cognitive assessments
Description: observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI brain, Blood tests, cognitive assessments
Description: observational study examining cognition post stroke using behavioural tests, MRI brain and blood tests
Study: NCT05971134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupreesure applied
Description: Acupressure was applied to the LI4 acupuncture point for 3 minutes by the researcher for the intervention group
Study: NCT04151875

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extraction orthodontic treatment
Description: orthodontic treatment with teeth extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-extraction orthodontic treatment
Description: Non-extraction orthodontic treatment
Study: NCT05262218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-680 10mg
Description: PBF-680 10mg administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally once a day
Study: NCT04364750

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: 1 capsule (0.6g) twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: 1 capsule (0.6g) twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Histidine
Description: 1 capsule (0.6g) twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-FODMAP beverage
Description: High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-FODMAP beverage
Description: High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-FODMAP beverage
Description: High-FODMAP beverage (10g of fermentable carbohydrates) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-FODMAP beverage
Description: Low-FODMAP beverage (10g glucose) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-FODMAP beverage
Description: Low-FODMAP beverage (10g glucose) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-FODMAP beverage
Description: Low-FODMAP beverage (10g glucose) consumed twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.
Description: Total of 50 billion CFU/capsule taken twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.
Description: Total of 50 billion CFU/capsule taken twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus CL1285, L. casei LBC80R and L. rhamnosus CLR2.
Description: Total of 50 billion CFU/capsule taken twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Enteric coated capsule with no active ingredient, taken twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Enteric coated capsule with no active ingredient, taken twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Enteric coated capsule with no active ingredient, taken twice daily
Study: NCT05915013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous ketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Intravenous ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Oral perampanel (6 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo
Study: NCT06386068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values-based Cognitive Behavioral Therapy (V-CBT)
Description: The intervention offers a 10-session treatment for chronic Whiplash-Associated Disorder (WAD). The manualized adapted version of value-based cognitive behavioral treatment (V-CBT) is conducted by interdisciplinary teams of psychologists and physiotherapists. The program, based on V-CBT principles, focuses on psychoeducation, fostering self-efficacy, and setting value-based goals in the initial three sessions. The subsequent seven sessions involve physiotherapists trained in V-CBT, addressing psychological, physical, social, and practical barriers hindering engagement in participants' lives. Each session combines psychologically informed themes and supervised exercises, aiming to enhance engagement in values-based activities.
Study: NCT06423963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Each participant will receive a Fitbit device with instruction and encouragement to self-monitor physical activity using step counts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive nutritional counseling with a registered dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Counseling
Description: Participants will receive nutritional counseling with a registered dietician.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will engage in progressive, full-body resistance training based on American College of Sports Medicine (ACSM) guidelines.
Study: NCT04789291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1595043
Description: Single dose of 30 milligram (mg) BI 1595043 as film coated tablets (1x 5mg tablet and 1x 25mg tablet).
Study: NCT05622682

Intervention type: OTHER
Intervention: Observational only: Serology and flow cytometry for ALL cohort participants
Description: Blood samples from ALL cohort participants will be tested to measure antibodies to vaccine-preventable diseases and immune recovery

Intervention type: OTHER
Intervention: Observational only: Infection rates
Description: Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.

Intervention type: OTHER
Intervention: Observational only: Infection rates
Description: Number of infections during the study period will be obtained from both ALL cohort and healthy control participants and captured for comparison and evaluation of infection rates during the first year off-chemotherapy.
Study: NCT05748392

Intervention type: DEVICE
Group type: OTHER
Intervention: Wound and per-wound assessments While using Device
Description: 3D imaging and wound and per-wound skin characteristics will be conducted initially, at dressing changes and at end of treatment/study.
Study: NCT06144736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted retroperitoneal lymph node dissection
Description: Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted retroperitoneal lymph node dissection
Description: Robot-assisted, if possibe ipsilateral nerve-sparing, retroperitoneal lymph node dissection and metastasis resection in a unilateral dissection field (template)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin
Description: The patient is given the option for an adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin two to four weeks after RA-RPLND
Study: NCT06158997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyePeace
Description: EyePeace a commercially available for enhancing meibum expression. The flexible, handheld device is made of silicone and provides regulated vertical pressure on closed eyelids (https://www.eyepeace.de). EyePeace will be used to assess its usefulness in improving evaporative dry eye signs and symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Eye Mask
Description: Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Eye Mask
Description: Heated Eye Mask will be used once a day to assess its usefulness in improving evaporative dry eye signs and symptoms.
Study: NCT04738097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 mg
Description: ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.
Study: NCT06292598

Intervention type: OTHER
Intervention: Blood sample
Description: Sample taken to test plasma permeability markers

Intervention type: OTHER
Intervention: Blood sample
Description: Sample taken to test plasma permeability markers

Intervention type: OTHER
Intervention: Stool sample
Description: Sample taken to test microbial diversity and composition

Intervention type: OTHER
Intervention: Stool sample
Description: Sample taken to test microbial diversity and composition

Intervention type: OTHER
Intervention: CSF sample
Description: Sample taken to test orexin level